Diligence memo · auto-generated · as of July 2, 2026
Axial Biotherapeutics, Inc.
Axial Biotherapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Axial Biotherapeutics, Inc. operates in Pharmaceuticals, based in WOBURN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Axial Biotherapeutics, Inc. has raised $110M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2021-05-11.
Most recent recorded round closed around 2025-01-28.
Valuation (modeled)modeled
Provath models Axial Biotherapeutics, Inc. at approximately $108M (range $41M–$173M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.97× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era. Within the normal band (97% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 17 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 56% of those peers.
Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Sensorium Therapeutics, Inc., Belhaven Biopharma Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.